[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-sclerosis-spasticity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-sclerosis-spasticity":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100576222",false,"NCT06782490","A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH\u002FMAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)","MSS","Inclusion Criteria\n\n* Participants must have a multiple sclerosis (MS) diagnosis.\n* Participants must have a history of spasticity due to MS for at least 6 months prior to Visit 1.\n* Participants must have a Modified Ashworth Scale (mAS) score ≥2 in each of 2 muscle groups (at least one muscle group in the leg, excluding ankle plantar flexors) at Visit 1.\n* Participants must have an Expanded Disability Status Scale (EDSS) score 3.0-6.5 at Visit 1.\n\nExclusion Criteria\n\n* Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity.\n* Participants must not have an acute MS exacerbation\u002Frelapse requiring treatment or alteration in disease modifying drug dose within 3 months of Visit 1 or Visit 2.\n* Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.\n* Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out by Visit 2.\n* Participants must not have used FAAH\u002FMAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to Visit 1.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years","70 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity",[27],"Multiple Sclerosis Spasticity",[29,30,31],"Spasticity","Multiple Sclerosis","BMS-986368","RECRUITING","2026-06-05",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":36},"2025-06-05",{"date":40,"type":21},"2027-06-09",{"name":42,"class":43},"Celgene","INDUSTRY",54,""]